1.10
  Price0.00%   +0
(After Hours: 1.10 0 +0.00%)
Calls Options of ARDS for (Expired in 12 days)
Strike Price Change % Change Volume
favorite 2.50 0.05 0.00 0.00% 0
favorite 5.00 0.00 0.00 0.00% 0
favorite 7.50 0.00 0.00 0.00% 0
Puts Options of ARDS for (Expired in 12 days)
Strike Price Change % Change Volume
favorite
2.50
0.00 0.00 0.00% 0
favorite
5.00
0.00 0.00 0.00% 0
favorite
7.50
0.00 0.00 0.00% 0
Aridis Pharmaceuticals Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb that is in Phase IIa trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 to treat infections caused by A. baumannii; AR-201, an anti- respiratory syncytial virus F-protein mAb; and AR-501, an anti-infective therapy to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals Inc. was founded in 2003 and is headquartered in San Jose, California.
Cap:    |  Volume (24h):